Considering that proteins such as Bruton’s tyrosine kinase (BTK) and Syk are also therapeutic targets17,20,21, it is possible that expression levels of other potential therapeutic targets within the BCR signalling pathway may also inform on CLL prognosis. The gene discussed is BTK; the disease is B-cell chronic lymphocytic leukemia.